New and Noteworthy Harvoni (ledipasvir + sofosbuvir) approved by Health Canada In October, Health Canada approved the hepatitis C medication Harvoni (ledipasvir + sofosbuvir) for people over the age of 18 with genotype 1 hepatitis C virus. In clinical trials, the cure rate for this combination was 94% to 100%. Ledipasvir and sofosbuvir are both… Read more »
CATIE: HepCinfo Update 5.23
Posted On: Wednesday, December 3rd, 2014